Daiichi Sankyo has received conditional approval from Japan’s Ministry of Health, Labour and Welfare for its oncolytic virus Delytact (teserpaturev/G-47delta) to treat malignant glioma. The approval marks the first-ever oncolytic virus therapy option to patients with glioblastoma and other malignant gliomas that are not controlled with currently available treatments. The therapy is Daiichi Sankyo’s fourth cancer medicine approved in Japan over the past two years.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Daiichi Sankyo wins approval in Japan for first-ever oncolytic virus therapy treating malignant glioma
CLINICAL
Artios heads to the clinic with first ever POLQ inhibitor trial
Artios Pharma Ltd. plans to begin the first clinical trials of a POLQ inhibitor class cancer drug later this year. There are a handful of companies working on POLQ inhibitor drugs, the name of the gene that encodes the enzyme DNA polymerase theta, but it looks like Artios has taken a head start following the publication of the supportive study in Nature Communications.
